Ron Shinkman

340B Providers Appear to Escape Bullet as Negotiations Continue on Build Back Better Bill’s Drug Pricing Provisions

In Federal, LegislativeNovember 11, 2021297 Views

The Build Back Better bill is still bogged down by infighting among Democrats, and its numerous drug pricing provisions will likely undergo changes prior to any votes.

Although Congress was able to pass a $1.2 trillion bipartisan infrastructure package last week, the nearly $1.8 trillion Build Back Better bill remains bogged down by infighting among Democrats.

Please Login or Become a Paid Subscriber

…

Limited Medicare Drug Price Negotiation Placed into Reconciliation Bill; 340B Impact Unclear

In Federal, LegislativeNovember 4, 2021204 Views

Ron Shinkman

U.S. Senate Majority Leader Chuck Schumer (D-N.Y.) announced on Tuesday that congressional Democrats and the White House reached agreement on federal drug pricing legislation. | C-SPAN

Democratic lawmakers have come to an agreement for placing a limited drug price negotiation plan for the Medicare program into the Build Back Better bill, but how it will impact the 340B program remains to be seen.

…

Sectyr Acquires LicenseTrak, Will Merge Capabilities into Single Platform

In Other IndustryNovember 2, 2021123 Views

Ron Shinkman

Sectyr, a major provider of compliance platforms for 340B covered entities, has bought LicenseTrak, a system for managing license, contract, training, and other business tasks.

Sectyr, an established provider of compliance platforms for 340B covered entities, has acquired LicenseTrak, a system for managing license, contract, training, and other business tasks, the companies announced last week.

Please Login or Become a Paid

…

California Still Plans to Move Medicaid Pharmacy Benefits to Fee-for-Service in January

In Regulatory, StateOctober 26, 2021311 Views

Ron Shinkman

California’s Medicaid (Medi-Cal) program remains on track to move its pharmacy benefit from managed care to fee-for-service early next year.

California’s Medicaid (Medi-Cal) program remains on track to move its pharmacy benefit from managed care to fee-for-service early next year, a change that would deprive federally qualified health centers and other safety net health care providers of hundreds of millions

…

340B Report Publisher and CEO: If Congress Flips Next Year, Expect 340B To Get A Very Close Look

In Federal, LegislativeOctober 19, 2021144 Views

Ron Shinkman

If Congress changes hands during next year’s mid-term elections, expect a renewed effort to place significant restrictions on the 340B program, 340B Report Publisher and CEO Ted Slafsky predicts.

If Congress changes hands during next year’s mid-term elections, we can expect the 340B program to be back under the spotlight with a renewed effort to place significant restrictions on the program, 340B Report Publisher and CEO Ted Slafsky writes

…

Drug Manufacturers May Seek Orphan Designations to Avoid Paying 340B Discounts, HHS OIG Concludes

In Federal, Research/ReportsOctober 14, 2021231 Views

Ron Shinkman

The 340B orphan drug exclusion incentivizes manufacturers to get orphan designations for drugs approved to treat common diseases or conditions, a new government report says.

The ban on 340B discounts on orphan drugs for rural and free-standing cancer hospitals may give drug companies a powerful incentive “to seek orphan designation for drugs approved to treat common diseases or conditions,” the U.S. Health and Human Services

…

Lifting of Title X Gag Rule Could Spur Hundreds of Clinics to Rejoin 340B

In Federal, RegulatoryOctober 12, 2021848 Views

Ron Shinkman

A September 2019 protest in Cleveland against the Trump administration rule barring Title X-funded family clinics from providing abortion referrals.

Hundreds of family planning clinics that lost their Title X federal grants and 340B eligibility because they opposed a Trump-era rule barring them from providing abortion referrals might return to Title X and 340B soon.

Please

…

340B Providers Might Insure HIV-at-Risk Patients in Response to Gilead’s PrEP Reimbursement Cuts

In Pharma IndustryOctober 5, 2021851 Views

Ron Shinkman

340B covered entities are bracing for a huge reimbursement cut due to start in January for Gilead pre-exposure prophylaxis (PrEP) medications.

340B covered entities are exploring buying health insurance for patients at risk of contracting HIV in response to a huge reimbursement cut due to start in January for Gilead pre-exposure prophylaxis (PrEP) medications.

Please Login or

…

Half of Congressional Black Caucus Asks CMS to End Medicare Drug Payment Cuts for 340B Hospitals

In Federal, LegislativeOctober 5, 2021195 Views

Ron Shinkman

Reps. Robin Kelly (D-Ill.), left, and Lisa Blunt Rochester (D-Del.), right, led the Sept. 24 letter urging CMS to end the nearly 30% cut in Medicare Part B drug payments to 340B hospitals.

Half of the Congressional Black Caucus (CBC) has asked Centers for Medicare & Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure to end the nearly 30% cut in Medicare Part B drug payments to 340B hospitals.